| Aug 12 |
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 12 |
Atara Biotherapeutics GAAP EPS of -$3.10 misses by $1.54, revenue of $28.64M misses by $8.45M
|
| Aug 12 |
Atara Biotherapeutics: Q2 Earnings Snapshot
|
| Aug 12 |
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
|
| Jul 19 |
US FDA grants priority review for Pierre Fabre’s EBV+ PTLD
|
| Jul 17 |
FDA priority review advances Atara’s tabelecleucel for viral infection
|
| Jul 17 |
Atara lead asset tab-cel undergoes FDA priority review
|
| Jul 17 |
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
|
| Jul 17 |
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
|
| Jul 15 |
All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy
|
